Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in
non-small cell lung cancer patients harboring uncommon EGFR mutation